A series of personal injury suits filed in Los Angeles earlier this month alleges that a charity established by the financier Michael Milken, in conjunction with prostate cancer researchers nationwide, engaged in systematic promotion of PC-Spes, a “nutraceutical” that was sold as a mixture of Chinese herbs, but was laced with prescription drugs.
Also in this 12-page issue: ASCO urges freeze of Medicare payments for chemotherapy at 2004 levels for next two years.
NCI director creates four new deputy director positions to manage the Institute.
Five NCAB members complete terms.
Breast surgeon and advocate Susan Love weds surgeon Helen Cooksey in San Francisco.
Funding opportunities listed.
NIH Director Zerhouni to discuss Roadmap initiatives Feb. 27.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
